Skip to content

Comparative Study of Autologous Blood Injection Versus Diluted Epinephrine in Treating Actively Bleeding Gastroduodenal Ulcers

Endoscopic Injection of Autologous Blood Versus Diluted Epinephrine for Control of Actively Bleeding Gastroduodenal Ulcers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01560702
Enrollment
100
Registered
2012-03-22
Start date
2012-03-31
Completion date
2013-09-30
Last updated
2013-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse Reaction to Epinephrine, Blood, Injection, Injury Type Phobia, Gastrointestinal Ulcer Haemorrhage

Keywords

autologous blood, epinephrine, endoscopy, ulcer, hemostasis

Brief summary

Endoscopic injection of autologous blood can control bleeding from gastroduodenal ulcers.

Detailed description

To test the hypothesis that endoscopic injection of autologous blood is superior to endoscopic injection of diluted epinephrine in controlling bleeding from gastroduodenal ulcers.

Interventions

DRUGEpinephrine

10-30 cc of 1/10000 diluted epinephrine will be injected at edges of an actively bleeding ulcer.

BIOLOGICALBlood

5-20 cc autologous blood immediately withdrawn from the patient will be injected at edges of the actively bleeding ulcer.

Sponsors

Zagazig University
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* all adult patients with gastroduodenal ulcer

Exclusion criteria

* Patients with non ulcer bleeding. * Patients with malignancy. * Patients with bleeding disorders or under coagulation therapy. * Patients with known allergy to epinephrine.

Design outcomes

Primary

MeasureTime frame
hemostasis from the ulcer after injection and/or stoppage of haematemesis and melena one day after the procedure.12 months

Secondary

MeasureTime frame
development of re-bleeding after 24 hours after the procedure (occurrence of hematemesis or melena or drop of hemoglobin level >2gm/dl).12 months

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026